Epirus Biopharmaceuticals
EPRS
EPRS was delisted on the 3rd of August, 2016.
41 hedge funds and large institutions have $64.9M invested in Epirus Biopharmaceuticals in 2015 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 11 closing their positions.
106% more capital inflows, than outflows
Capital inflows: $5.56M | Capital outflows: $2.7M
0% more funds holding
Funds holding: 41 → 41 (0)
0% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 11
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $494K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.23M |
| 2 |
Bailard
Foster City,
California
|
+$796K |
| 3 |
TC
TFS Capital
West Chester,
Pennsylvania
|
+$386K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$376K |
| 5 |
Consonance Capital Management
New York
|
+$345K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lombard Odier Asset Management (USA)
New York
|
-$724K |
| 2 |
BlackRock Advisors
Wilmington,
Delaware
|
-$393K |
| 3 |
BlackRock Institutional Trust
San Francisco,
California
|
-$304K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$230K |
| 5 |
Jennison Associates
New York
|
-$217K |
EPRS Hedge Fund Activity: Q3 2015 in Review
41 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Epirus Biopharmaceuticals (EPRS) for Q3 2015, worth a combined $64.9M — down 20% from $81M a quarter earlier.
Fund positioning in EPRS was balanced in Q3 2015: 11 funds opened new positions, 11 closed out, 9 added to existing stakes and 12 trimmed.
The largest buyer was Millennium Management, adding an estimated $2.23M. The largest seller was Lombard Odier Asset Management (USA), exiting entirely with an estimated $724K sold.
- 41 institutional investors held Epirus Biopharmaceuticals (EPRS) as of Q3 2015, unchanged from Q2 2015.
- Funds reported $64.9M of Epirus Biopharmaceuticals stock for Q3 2015, down 20% quarter-over-quarter.
- 11 funds opened new Epirus Biopharmaceuticals positions in Q3 2015 and 11 closed out, a net change of 0 holders.
- The largest Epirus Biopharmaceuticals buyer in Q3 2015 was Millennium Management, an estimated $2.23M added.
- The largest Epirus Biopharmaceuticals seller in Q3 2015 was Lombard Odier Asset Management (USA), an estimated $724K sold.
Based on aggregated 13F filings for Q3 2015.